Molecule Flips Switch on Gene Regulation

Abstract A new class of designer drugs can reprogram gene expression by linking a transcription factor that silences genes involved in cell death with an epigenetic regulator that stimulates gene activity. A prototype molecule showed robust potency in flipping the function of BCL6, a protein that supports lymphoma cell proliferation, offering a promising therapeutic approach to combat cancer cell growth.